Non-Radiographic Axial Spondylarthritis
FDA OKs Bimzelx for psoriatic arthritis, ankylosing spondylitis, non-radiographic axSpA
The FDA has expanded the indication of Bimzelx to include psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthritis with objective signs of inflammation, according to a press release.
Knowing ‘fluid’ nature of axial spondyloarthritis critical to preventing serious outcomes
ORLANDO, Fla. — Understanding the nuances of spondyloarthropathy diagnostic criteria can help prevent “debilitating” consequences, according to a presenter at the 2024 Rheumatology Nurses Society annual conference.
Treatment Recommendations & Guidelines
TNF Inhibitor Therapy
Treatment Recommendations & Guidelines
Assessment and Monitoring
Classification Criteria
Etiology and Pathogenesis
FDA approves intravenous formulation of secukinumab
The FDA has approved an intravenous formulation of Cosentyx for use in patients with psoriatic arthritis, ankylosing spondylitis and nonradiographic axial spondyloarthritis, according to a press release from Novartis.
FDA approves upadacitinib for non-radiographic axial spondyloarthritis
The FDA has approved upadacitinib for the treatment of non-radiographic axial spondyloarthritis, marking the sixth indication for the therapy, according to a press release from AbbVie.